$ANIX
Anixa Biosciences Inc Stock $anix

$anix Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223000346 Filed on January 04, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.488M	$1.924M	$7.172M
YoY Change	-27.13%	1.06%	1.39%
% of Gross Profit
Research & Development	$1.068M	$1.685M	$6.703M
YoY Change	-41.89%	-22.47%	8.29%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.068M	$3.609M	$6.703M
YoY Change	-72.47%	-11.48%	-49.46%
Operating Profit	-$2.556M		-$13.88M
YoY Change	-34.12%		5.63%
Interest Expense	$202.0K	$80.00K	$104.0K
YoY Change	20100.0%	14445.45%	4382.76%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.354M	-$3.529M	-$13.77M
YoY Change	-39.31%	-13.31%	4.9%
Income Tax
% Of Pretax Income
Net Earnings	-$2.322M	-$3.476M	-$13.60M
YoY Change	-39.36%	-13.39%	4.95%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.08		-$0.45
Diluted Earnings Per Share	-$0.08	-$113.0K	-$447.6K
COMMON SHARES
Basic Shares Outstanding	30.92M shares		30.37K shares
Diluted Shares Outstanding	30.92K shares		30.37M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.70M	$29.69M	$29.69M
YoY Change	-19.77%	-16.91%	-16.91%
Cash & Equivalents	$9.790M	$12.36M	$12.36M
Short-Term Investments	$17.91M	$17.33M	$17.33M
Other Short-Term Assets	$256.0K	$513.0K	$513.0K
YoY Change	-44.83%	86.17%	86.17%
Inventory
Prepaid Expenses
Receivables	$147.0K
Other Receivables	$0.00
Total Short-Term Assets	$28.11M	$30.20M	$30.20M
YoY Change	-19.69%	-16.12%	-16.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$201.0K	$212.0K	$212.0K
YoY Change	-17.62%	-16.52%	-16.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$201.0K	$212.0K	$212.0K
YoY Change	-17.62%	-16.52%	-16.52%
TOTAL ASSETS
Total Short-Term Assets	$28.11M	$30.20M	$30.20M
Total Long-Term Assets	$201.0K	$212.0K	$212.0K
Total Assets	$28.31M	$30.41M	$30.41M
YoY Change	-19.67%	-16.12%	-16.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$110.0K	$265.0K	$265.0K
YoY Change	-78.17%	94.57%	94.57%
Accrued Expenses	$1.075M	$1.726M	$1.772M
YoY Change	-16.21%	52.16%	56.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.232M	$2.037M	$2.037M
YoY Change	-31.06%	60.33%	60.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$162.0K	$175.0K	$175.0K
YoY Change	-22.49%	-20.48%	-20.48%
Total Long-Term Liabilities	$162.0K	$175.0K	$175.0K
YoY Change	-22.49%	-20.48%	-20.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.232M	$2.037M	$2.037M
Total Long-Term Liabilities	$162.0K	$175.0K	$175.0K
Total Liabilities	$1.394M	$2.212M	$1.365M
YoY Change	9.33%	169.72%	66.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$220.7M	-$218.4M
YoY Change		6.64%
Common Stock	$309.0K	$309.0K
YoY Change		2.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.79M	$29.05M	$29.05M
YoY Change
Total Liabilities & Shareholders Equity	$28.31M	$30.41M	$30.41M
YoY Change	-19.67%	-16.12%	-16.12%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.322M	-$3.476M	-$13.60M
YoY Change	-39.36%	-13.39%	4.95%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.988M	-$1.593M	-$6.492M
YoY Change	66.08%	52.56%	31.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$585.0K	-$9.917M	-$10.73M
YoY Change	-131.62%	-453.34%	173.84%
Cash From Investing Activities	-$585.0K	-$9.917M	-$10.73M
YoY Change	-131.62%	-453.34%	173.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.000K	-384.0K	$452.0K
YoY Change		-367.37%	-98.57%
NET CHANGE
Cash From Operating Activities	-$1.988M	-1.593M	-$6.492M
Cash From Investing Activities	-$585.0K	-9.917M	-$10.73M
Cash From Financing Activities	$3.000K	-384.0K	$452.0K
Net Change In Cash	-$2.570M	-11.89M	-$16.77M
YoY Change		-723.99%	-173.83%
FREE CASH FLOW
Cash From Operating Activities	-$1.988M	-$1.593M	-$6.492M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000715446
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2021	ANIX	Common Stock Issued To Consultants CommonStockIssuedToConsultants		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	ANIX	Proceeds Received On Sale Of Common Stock By Zqx Advisors Llc ProceedsReceivedOnSaleOfCommonStockByZqxAdvisorsLlc		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	ANIX	Operating Lease Right Of Use Asset Non Cash Investing Activity OperatingLeaseRightOfUseAssetNonCashInvestingActivity		usd
CY2022	ANIX	Operating Lease Liability Non Cash Financing Activities OperatingLeaseLiabilityNonCashFinancingActivities		usd
CY2022	ANIX	Fair Value Of Warrants Issued In Connection With Public Offering FairValueOfWarrantsIssuedInConnectionWithPublicOffering		usd
CY2022Q4	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber		shares
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Assets Assets	30412000	usd
CY2021Q4	us-gaap	Assets Assets	36257000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-10-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--10-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37492
CY2022	dei	Entity Registrant Name EntityRegistrantName	ANIXA BIOSCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2622630
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3150 Almaden Expressway
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Jose
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95118
CY2022	dei	City Area Code CityAreaCode	(408)
CY2022	dei	Local Phone Number LocalPhoneNumber	708-9808
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2022	dei	Trading Symbol TradingSymbol	ANIX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	93235194	usd
CY2022Q2	dei	Entity Public Float EntityPublicFloat	93235194	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30920792	shares
CY2022	dei	Auditor Firm AuditorFirmId	200
CY2022	dei	Auditor Name AuditorName	HASKELL & WHITE LLP
CY2022	dei	Auditor Location AuditorLocation	Irvine, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12360000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29128000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	17327000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	6599000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	513000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	276000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	30200000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	36003000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	254000	usd
CY2022Q4	us-gaap	Assets Assets	30412000	usd
CY2021Q4	us-gaap	Assets Assets	36257000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	265000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	136000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1726000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1095000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2037000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1270000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	175000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	220000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2212000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1490000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	100
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	100
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	19860	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	19860	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30913902	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30913902	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30050894	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30050894	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	309000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	301000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	247123000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	239927000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218385000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-204790000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29047000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35438000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-847000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-671000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28200000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34767000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30412000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36257000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	512000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	385000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6703000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6190000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7172000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7073000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	13875000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	13648000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13875000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13136000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	104000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	2000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-13771000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-13128000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-176000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-174000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13595000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12954000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30374000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28579000	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8264000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7503000	usd
CY2021	ANIX	Adjustments To Additional Paid In Capital Stock Option And Warrants Issued Value AdjustmentsToAdditionalPaidInCapitalStockOptionAndWarrantsIssuedValue	555000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	434000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	6000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2208000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	20292000	usd
CY2021	ANIX	Expenses Of Atthemarket Offering ExpensesOfAtthemarketOffering	341000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10834000	usd
CY2021	ANIX	Adjustments To Additional Paid In Capital Proceeds Received On Sale Of Common Stock Held By Zqx Advisors Llc AdjustmentsToAdditionalPaidInCapitalProceedsReceivedOnSaleOfCommonStockHeldByZqxAdvisorsLlc	7000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-13128000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34767000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34767000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6000000	usd
CY2022	ANIX	Adjustments To Additional Paid In Capital Stock Option And Warrants Issued Value AdjustmentsToAdditionalPaidInCapitalStockOptionAndWarrantsIssuedValue	655000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	439000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	97000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	13000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-13771000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28200000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28200000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	42000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-13771000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-13128000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6000000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7503000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	655000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	555000	usd
CY2022	ANIX	Common Stock Issued To Consultants CommonStockIssuedToConsultants	97000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	60000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	237000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-36000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	129000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-96000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	631000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	193000	usd
CY2022	ANIX	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-38000	usd
CY2021	ANIX	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-55000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6492000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4938000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	22486000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	16498000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	11758000	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	12539000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	35000	usd
CY2021	ANIX	Proceeds Received On Sale Of Common Stock By Zqx Advisors Llc ProceedsReceivedOnSaleOfCommonStockByZqxAdvisorsLlc	7000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10728000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3917000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	20292000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10834000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	13000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	6000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	439000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	434000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	452000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31566000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16768000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22711000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29128000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6417000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12360000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29128000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	23000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2021	ANIX	Operating Lease Right Of Use Asset Non Cash Investing Activity OperatingLeaseRightOfUseAssetNonCashInvestingActivity	-259000	usd
CY2021	ANIX	Operating Lease Liability Non Cash Financing Activities OperatingLeaseLiabilityNonCashFinancingActivities	259000	usd
CY2021	ANIX	Fair Value Of Warrants Issued In Connection With Public Offering FairValueOfWarrantsIssuedInConnectionWithPublicOffering	1041000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000000	usd
CY2020Q4	us-gaap	Minority Interest MinorityInterest	-497000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-174000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-671000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-176000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-847000	usd
CY2022Q4	ANIX	Revenue Recognized Percentage RevenueRecognizedPercentage	1	pure
CY2022Q4	ANIX	Money Market Funds Cash And Cash Equivalents MoneyMarketFundsCashAndCashEquivalents	11175000	usd
CY2022Q4	ANIX	Certificates Of Deposit Cash And Cash Equivalents CertificatesOfDepositCashAndCashEquivalents	1000000	usd
CY2022Q4	ANIX	Certificates Of Deposit Short Term Investments CertificatesOfDepositShortTermInvestments	13700000	usd
CY2022Q4	ANIX	Treasury Bills And Bonds Short Term Investments TreasuryBillsAndBondsShortTermInvestments	3627000	usd
CY2022Q4	ANIX	Financial Assets FinancialAssets	29502000	usd
CY2021Q4	ANIX	Money Market Funds Cash And Cash Equivalents MoneyMarketFundsCashAndCashEquivalents	28949000	usd
CY2021Q4	ANIX	Certificates Of Deposit Short Term Investments CertificatesOfDepositShortTermInvestments	2000000	usd
CY2021Q4	ANIX	Treasury Bills And Bonds Short Term Investments TreasuryBillsAndBondsShortTermInvestments	4599000	usd
CY2021Q4	ANIX	Financial Assets FinancialAssets	35548000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.93
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M3D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M28D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0272	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0902	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0199	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0069	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	17327	usd
CY2021Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	6599	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5141000	usd
CY2022	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P1Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.18
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zlxIVqidVyfa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zcCys3s1pqCg">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are used for, but not limited to, determining stock-based compensation, asset impairment evaluations, tax assets and liabilities, license fee revenue, the allowance for doubtful accounts, depreciation lives and other contingencies. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zRWVB4dgxA9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zrpHal8xZHB5">Concentration of Credit Risks</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject us to concentrations of credit risk are cash equivalents, short-term investments and accounts receivable. Cash equivalents are primarily highly rated money market funds. Short-term investments are certificates of deposit within federally insured limits as well as U.S. treasury bills. Where applicable, management reviews our accounts receivable and other receivables for potential doubtful accounts and maintains an allowance for estimated uncollectible amounts. Our policy is to write-off uncollectable amounts at the time it is determined that collection will not occur. One licensee accounted for 100% of revenues from patent licensing activities during fiscal year 2021.</span></p>
CY2022Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	1144000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	492000	usd
CY2022Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	577000	usd
CY2021Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	577000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	5000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	26000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1726000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1095000	usd
CY2022	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	793103	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1083517	shares
CY2021	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	207697	shares
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	60691	shares
CY2021Q4	ANIX	Federal And State Nol And Tax Credit Carryforwards FederalAndStateNOLAndTaxCreditCarryforwards	20230000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	6851000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	7502000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	274000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	330000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	281000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	219000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1698000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.58
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.58
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1642000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.58
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1642000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.58
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.85	pure
CY2021Q4	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	25484	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	560000	shares
CY2020Q4	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	4.71
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	300000	shares
CY2021	ANIX	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	6.56
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	860000	shares
CY2021Q4	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	5.36
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	60000	shares
CY2022	ANIX	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	4.77
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	60000	shares
CY2022	ANIX	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePriceExercised	2.06
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	560000	shares
CY2022	ANIX	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePriceExpired	4.71
CY2022Q4	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	300000	shares
CY2022Q4	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	6.56
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	66000	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	64000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29602000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28281000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29602000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28281000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	66000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	67000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	70000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	65000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	268000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	47000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	221000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1021000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	604000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-350000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-129000	usd
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	1371000	usd
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-475000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-13128000	usd
CY2022Q4	ANIX	Federal And State Nol And Tax Credit Carryforwards FederalAndStateNOLAndTaxCreditCarryforwards	22196000	usd
CY2022	ANIX	Valuation Allowance Deferred Tax Asset Percentage ValuationAllowanceDeferredTaxAssetPercentage	1	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2892000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2757000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-962000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0698	pure
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-917000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0698	pure
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	14000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0010	pure
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	23000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0017	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	2469000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.1793	pure
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4126000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.3143	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1371000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0995	pure
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-475000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0362	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2022	us-gaap	Profit Loss ProfitLoss	-13771000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-13128000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-13771000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	13875000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	13648000	usd
CY2022	ANIX	Noncash Sharebased Compensation NoncashSharebasedCompensation	-6655000	usd
CY2021	ANIX	Noncash Sharebased Compensation NoncashSharebasedCompensation	-8058000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7220000	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5590000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7220000	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5590000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7220000	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5590000	usd
CY2022Q4	us-gaap	Assets Assets	30412000	usd
CY2021Q4	us-gaap	Assets Assets	36257000	usd
CY2021	us-gaap	Revenues Revenues	512000	usd
CY2021	ANIX	Royalty Expense And Licensing Expense RoyaltyExpenseAndLicensingExpense	385000	usd

Files In Submission

Name	View Source	Status
0001493152-23-000346-index-headers.html	Edgar Link	pending
0001493152-23-000346-index.html	Edgar Link	pending
0001493152-23-000346.txt	Edgar Link	pending
0001493152-23-000346-xbrl.zip	Edgar Link	pending
anix-20221031.xsd	Edgar Link	pending
anix-20221031_def.xml	Edgar Link	unprocessable
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
anix-20221031_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
anix-20221031_cal.xml	Edgar Link	unprocessable
anix-20221031_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIX
Anixa Biosciences Inc Stock $anix

2023 Q1 Form 10-K Financial Statement

#000149315223000346 Filed on January 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIX Anixa Biosciences Inc Stock $anix

2023 Q1 Form 10-K Financial Statement

#000149315223000346 Filed on January 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIX
Anixa Biosciences Inc Stock $anix